Despite Dropping Out of University, This Billionaire Scored a 1,000% Gain on Biotech Shares
Success is not always reserved for those with high levels of education. Bob Duggan, a successful entrepreneur, has secured substantial profits from investments in biotechnology stocks. His recent investment in Summit Therapeutics (SMMlar) has surged by more than 1,000%.
According to The Wall Street Journal, the surge in the biopharmaceutical company’s shares occurred due to data from late-stage clinical trials showing that its drug, Ivonescimab, outperformed Merck’s blockbuster cancer drug, Keytruda, in patients with lung cancer.
Duggan, who was already a billionaire before his investment in Summit, is now estimated to have a net worth of approximately US$16 billion, or around Rp 243.1 trillion. Nevertheless, several challenges remain regarding this drug, including its performance in global trials outside of China, where Summit licensed Ivonescimab from the Chinese biotechnology firm Akeso in 2022.
This is not the first time Duggan has achieved success in the biotechnology world. Two decades ago, he invested in Pharmacyclics, a company that developed the cancer drug Imbruvica. After facing various challenges, Pharmacyclics was eventually acquired by AbbVie for US$21 billion, establishing Duggan as a key figure in the industry.
Duggan, who is now 80 years old, has proven that success in this industry is not exclusive to those with high academic backgrounds. Nathan Vardi, author of “For Blood and Money,” notes that while many argue Duggan is merely lucky, his ability to determine when to hold or exit an investment is the key to his success.
Duggan’s experience across various industries, ranging from bread to robotics, provides him with a different perspective when facing challenges. He believes that the lack of understanding as an outsider, combined with the intensity he brings, allows him to take unconventional steps.
Ivonescimab, for instance, does not only function as a PD-1 protein binder to trigger the immune system but also inhibits the VEGF protein that supports tumour blood vessel growth. This drug possesses a dual mode of action, which is expected to provide a more potent effect in fighting cancer.
However, experts warn that this dual action could lead to safety issues in the future. Given the recorded side effects of drugs targeting VEGF, analysts are awaiting further data to ensure the drug is safe and can improve patient survival rates.
While Summit has the opportunity to compete in the US$50 billion PD-1 market, the challenges in execution remain significant. Analysts warn that success will depend heavily on proper management and effective trial design strategies.
As the market digests the magnitude of the challenges facing Summit, the company’s shares are expected to remain volatile and could experience a decline following the price surge post-data release. With all eyes on Ivonescimab, the future of Duggan and Summit will be a focal point for investors and analysts worldwide.
Source: jawawa.id (https://jawawa.id/newsitem/despite-dropping-out-of-university-this-billionaire-scored-a-1-000-gain-on-biotech-shares-1781178867)
Originally published by CNBC Indonesia (https://www.cnbcindonesia.com/market/20260611162233-17-742083/tak-lulus-kuliah-orang-ini-malah-untung-1000-di-saham-biotech), translated from Indonesian